Vesugen (KED): the vascular bioregulator peptide
Vesugen is the trade name for the tripeptide Lys-Glu-Asp (KED), marketed as a 'vascular bioregulator.' Here's what the endothelial research actually shows — and what it doesn't.
How It Works
In cultured endothelium modeling atherosclerosis and restenosis, KED normalized the elevated expression of endothelin-1 and restored connexin-mediated cell-to-cell coupling — a proposed vasoprotective signal (Adv Gerontol 2016, PMID 28539025).
Vesugen stimulated the proliferation marker Ki-67, which declines with age, in dissociated vascular endothelial cell cultures; molecular docking maps the peptide to the MKI67 gene promoter — the basis of its proposed epigenetic mechanism (Adv Gerontol 2014, PMID 25051766).
A review of cardiovascular-system senescence places KED among vasoprotective peptides that may regulate the senescence-associated secretory phenotype and inflammaging signaling (p16/p21, IL-6, NF-κB, sirtuins) in vessel-wall cells (Cells 2022, PMID 36611900).
A molecular-genetic paper describes KED in the context of neurogenesis regulation in Alzheimer's disease — a mechanistic, neurological readout, not vascular, and not a clinical or oral-bioavailability study (Bull Exp Biol Med 2021, PMID 34173097).
What the Data Shows
Key Takeaways
- Vesugen is the commercial name for KED (Lys-Glu-Asp), a Khavinson 'short-peptide bioregulator' targeted at the vascular system.
- In vitro, KED normalized atherosclerosis-elevated endothelin-1 and restored connexin coupling in endothelial cultures (PMID 28539025).
- Vesugen stimulated the proliferation marker Ki-67 in aged vascular endothelial cells, with a proposed epigenetic action on the MKI67 promoter (PMID 25051766).
- Reviews group KED among vasoprotective peptides that may modulate SASP/inflammaging signaling in cardiovascular cells (PMID 36611900).
- A molecular-genetic paper discusses KED in the context of neurogenesis regulation in Alzheimer's disease — a mechanistic, neurological readout, not vascular and not an oral-bioavailability study (PMID 34173097).
- Nearly all primary evidence comes from one group (Khavinson / St. Petersburg Institute of Bioregulation and Gerontology) — no independent replication.
- There are no randomized, placebo-controlled trials; the human data is small and open-label.
- Most mechanistic findings are in vitro or molecular docking — not proof of clinical endothelial benefit in people.
- 'Restores endothelial function' overstates what small uncontrolled studies can establish.
- No Western regulatory approval; dosing is not standardized and product quality is unverified.
- Effects on hard cardiovascular endpoints and long-term safety are unstudied.
Frequently Asked Questions
What is Vesugen?
Vesugen is the trade name for KED, the tripeptide Lys-Glu-Asp. It is one of the Khavinson 'bioregulator' short peptides, marketed for the vascular system and studied mostly in vitro and in small Russian clinical reports.
Is Vesugen the same as KED?
Yes. Vesugen (also spelled Vezugen) is the commercial name for the Lys-Glu-Asp (KED) tripeptide; the research literature uses the names interchangeably.
Does Vesugen actually restore endothelial function?
The honest answer is unproven. KED normalized endothelin-1 and stimulated endothelial-cell proliferation markers in cell cultures — but these are in vitro findings, there are no randomized controlled trials, and almost all data come from a single research group.
How is Vesugen taken?
In the Russian literature KED is given orally in short courses. Oral bioavailability has not been established in published pharmacokinetic studies, dosing is not standardized, and no regulatory body has set guidelines.
Is the evidence for Vesugen strong?
No. The evidence base is preliminary: mostly in vitro and molecular-docking work with no controlled human vascular trial, all from one institute. Treat 'endothelial restoration' claims as a hypothesis, not an established effect.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for every batch. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Vesugen/KED is a research compound. It is not approved by Western regulators and the human evidence is preliminary and single-source. Consult a qualified clinician before use.